Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Q1 FY2022 Earnings Presentation
29 slides from Genetic Technologies's earnings presentation, Oct 26, 2021
Slide 1: Quarterly Business Update
For personal use only Quarterly Business Update October 2021 ASX: GTG Authorised by the Board of Directors of Genetic Technologies Limited NASDAQ: GENE
Slide 2: Notice: Forward looking statements
For personal use only Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they
Slide 3: Unlocking personalised preventative health
Unlocking For personal use only personalised preventative health Significant progress has been made in understanding the role of hereditary risk in chronic disease, however, many chronic conditions cannot be predicted by this risk alone. We’re transforming the conversation. Transitioning from a one-
Slide 4: Our Overview
Our Overview For personal use only 01 02 03 04 05 06 Our Vision & Our Markets Our Acquisition Our Channels & Our Portfolio & Our Capabilities Brand Pillars Divisions Innovation 2021 Overview Prioritising the EasyDNA - Building our Focused on three Executing through cutting Aligning our internal Wher
Slide 5: Highlights and Results overview – Qtr. 1, 2021
Highlights and Results overview – Qtr. 1, 2021 For personal use only • Cash receipts of A$850k, a material increase on the prior quarter Receipts from Customers 850 • Acquired, settled and integrated the acquisition of EasyDNA, the primary channel for the increase in cash from operations, for US$4 m
Slide 6: Our 2021 Snapshot
01: Our 2021 Snapshot For personal use only Signed multi-year distribution agreement Acquired revenue generating platform License and distribution agreement for COVID-19 Risk Acquired EasyDNA for US$4m in cash and script2 Test with IBX providing global platform with US$4.63m in Launched CIT in USA &
Slide 7: Our Markets and Collaborators
02: Our Markets and Collaborators For personal use only United States Europe & UK Asia Australia & New Zealand (Inc. SEA, China and India) geneType® Polygenic Risk Commencing CE certification H2 CY2021 to commence a Certification by Australian Score (PRS) tests for breast, enabling EU launch of Nove
Slide 8: A strategy to own the personalised, preventative health testing market
02: A strategy to own the personalised, preventative health testing market For personal use only Brand Recognition and Advocacy Commercialization and Branding Thought leadership Sales & marketing Demonstrating our leadership by informing the Core set of sales and marketing tactics and assets convers
Slide 9: A cutting-edge geneType brand set for relaunch
02: A cutting-edge geneType brand set for relaunch For personal use only Digital Mobile Education
Slide 10: Core set of sales material to empower clinicians and consumers
02: Core set of sales material to empower clinicians and consumers to trial and use geneType tests For personal use only At-a-glance HCP brochure Guide Book Patient Management case studies guide Clinical Patient Summaries booklet Expert Clinic interviews poster
Slide 11: EasyDNA – Acquisition of DTC Platform
03: EasyDNA – Acquisition of DTC Platform For personal use only • Acquired EasyDNA in August 2021 for US$4 million • Current revenues of US$4.63 million through retail sales of its at- home DNA tests • Agreements with 12 laboratories in North America, AsiaPac and Europe • A platform to launch the ge
Slide 12: EasyDNA – Establishing our Lifestyle Division
03: EasyDNA – Establishing our Lifestyle Division For personal use only • Headed by Kevin Camilleri • EasyDNA currently sells paternity, oncology and health and wellbeing genomics-based tests • This acquisition provides Genetic Technologies the foundation to grow in 40 countries • Expand the health-
Slide 13: Our Pathways
04: Our Pathways For personal use only Medical – Business to Business Consumer initiated testing (CIT) Direct to consumer testing (DTC) (B2B) with medical supervision with no medical supervision A communication Certifying Launched US and Current products Recent Acquisition Provides Genetic and execu
Slide 14: Our Divisions
04: Our Divisions For personal use only Emerging divisions Pharmoco- Oncology BC, CRC, PC, Genetics & NEW – Universal collection test kit Existing divisions Companion Melanoma diagnostics to support Multi Test Launch CVD Germline testing (Heart Disease) BRCA, Lynch IHD, AF Syndrome and Somatic testi
Slide 15: Our Innovation
05: Our Innovation For personal use only geneType integrates genetic risk and clinical risk to better stratify individual risk. Patients with potentially high risk may exceed actionable clinical guidelines 10 – 15 years earlier than those with low risk 1,2,3 Breast Cancer (BC)1 Colorectal Cancer (CR
Slide 16: Our Portfolio − Driving Growth
05: Our Portfolio − Driving Growth For personal use only ` ` Moderate CIT Platform in AUS and Revenue USA selling BRC and CRC Expectations Q2 CY 2021 IBX COVID Risk Test Revenue released for sale May 31, Commenced 2021 Q2 CY 2021 Expanding into reimbursable 100% Germline + PRS test space Commerciall
Slide 17: Significant market opportunity
05: Significant market opportunity To provide predictive, pre-symptomatic testing to inform lifestyle choices and healthcare discussions For personal use only Guideline driven, reimbursable for inherited and non inherited disease Near Term Addressable Market GTG Target Market for BRCA Panel + Breast
Slide 18: Our Innovation - Multi Test
05: Our Innovation - Multi Test A companion diagnostic PRS to help identify risk of serious disease for up to 70% of Mortalities and Morbidities For personal use only Committed to continually invest in developing multi population testing solutions Phase 1 Launch 2 Oncology GeneType Multi-test to inc
Slide 19: Our Innovation - Multi Test
05: Our Innovation - Multi Test Phase 1 Launch Test reports – NATA Validation pack submitted For personal use only Phase 1 Launch 2 Phase 2 Launch 3 1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek 2. Commercial availability expected Q4 CY2021 3. Commercial availability exp
Slide 20: Our Capability
06: Our Capability For personal use only Dedicated Innovation Hub Developing and capturing the next generation of innovation in genomics Marketing and Positioning Enhanced Sales and Distribution Creating a consumer and patient led Capitalise on Licensing, JV and M&A opportunities infrastructure for
Slide 21: Targeted and Positioned for deliberate growth
For personal use only 01 02 03 04 05 06 Our Vision & Our Markets Our Acquisition Our Channels & Our Portfolio & Our Capabilities Brand Pillars Divisions Innovation Targeted and Positioned for Focused and Cutting edge Aligned to deliberate growth distinct innovation execute 21
Slide 22: Thank you
For personal use only Thank you Corporate Simon Morriss Genetic Technologies Investor Relations Stephanie Ottens +61 434 405 400 simon.morriss@gtglabs.com stephanie.ottens@marketeye.com.au
Slide 23: Appendices
For personal use only Appendices
Slide 24: Our Intellectual Property
Our Intellectual Property For personal use only 7 Patents granted in the US 9 Patent families pending • Patent 11,031,098, Computer systems and methods for genomic analysis • Methods for breast cancer risk assessment • Patent 10,683,549, Methods for assessing risk of developing breast cancer • Metho
Slide 25: Board and Management
Board and Management: Sales and Scientific expertise leading GTG For personal use only Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Com, FAICD, FCA, Chairman - Non – Executive Non – Executive Director FGIA, FTIA, F Fin Director Non – Executive Director Dr. Jerzy “George
Slide 26: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board For personal use only Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MWGO is MD, MS, FACMG Research & Education Lead, Primary Care Principal Fellow and Professor, Department Regio
Slide 27: Financial Overview
Financial Overview For personal use only • Cash burn of A$1.94 million a decrease on prior quarter (Q4 FY’21: A$2.12 million) as a result of product sales, mainly from the EasyDNA brand $A’000 30 June 30 Sep Change 2021 2021 • Cash reserves of A$15.7 million after EasyDNA acquisition costs of A$3.5
Slide 28: Corporate Overview
Corporate Overview For personal use only Top 50 share registry breakdown Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 18 October 2021 0.7c Other, 20% ADR price (USD) as at 18 October 2021 $3.00 Ord Shares on Issue (M) 9,226 Board & Management , ASX 52-week trading
Slide 29: Defined Terms
Defined Terms For personal use only Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score
Genetic Technologies — Q1 FY2022 Earnings Presentation on 6ix